SQZ Biotechnologies Company (SQZB)

OTCMKTS: SQZB · Delayed Price · USD
0.0380
+0.0025 (7.04%)
Feb 26, 2024, 3:59 PM EST - Market closed
Market Cap 825.75K
Revenue (ttm) 18.61M
Net Income (ttm) -76.11M
Shares Out 29.49M
EPS (ttm) -2.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,684,756
Open 0.0356
Previous Close 0.0355
Day's Range 0.0355 - 0.0400
52-Week Range 0.0101 - 0.2900
Beta 1.67
Analysts n/a
Price Target n/a
Earnings Date n/a

About SQZB

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 30, 2020
Employees 53
Stock Exchange OTCMKTS
Ticker Symbol SQZB
Full Company Profile

Financial Performance

In 2022, SQZB's revenue was $21.48 million, a decrease of -20.74% compared to the previous year's $27.10 million. Losses were -$79.46 million, 15.6% more than in 2021.

Financial Statements

News

SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial resul...

3 months ago - Business Wire

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatme...

4 months ago - Business Wire

SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported second quarter 2023 financial results and recent p...

7 months ago - Business Wire

SQZ Biotechnologies Provides Update on Collaboration with Roche

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive s...

7 months ago - Business Wire

NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of S...

8 months ago - Business Wire

SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (the “Company” or “SQZ”), focused on unlocking the full potential of cell therapies, today announced that its Board of Direct...

9 months ago - Business Wire

SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent po...

10 months ago - Business Wire

SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirm...

1 year ago - Business Wire

SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfo...

1 year ago - Business Wire

SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ) today announced that on January 18, 2023, it received notice from the New York Stock Exchange (NYSE) indicating that the Company is...

1 year ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such investors are advised to ...

1 year ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SQZ Biotechnologies Company - SQZ

New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such invest...

1 year ago - Newsfile Corp

Bronstein, Gewirtz & Grossman, LLC Announces SQZ Biotechnologies Company (SQZ) Investigation

NEW YORK , Dec. 7, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against SQZ Biotechnologies Company ("SQZ" or "the Company") (NYSE:...

1 year ago - PRNewsWire

SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company's Enhan...

1 year ago - Business Wire

SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ) today announced the strategic prioritization of its clinical portfolio to concentrate on the development of its second-generation e...

1 year ago - Business Wire

SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of...

1 year ago - Business Wire

SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical data s...

1 year ago - Business Wire

SQZ Biotechnologies to Present at Upcoming Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei,...

1 year ago - Business Wire

SQZ Biotechnologies Announces Leadership Transition

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernst...

1 year ago - Business Wire

SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2022 financi...

1 year ago - Business Wire

SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of...

1 year ago - Business Wire

SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Mica...

1 year ago - Business Wire

SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented Tolerizing Antigen...

1 year ago - Business Wire